● Recruiting

TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Condition: Bladder Cancer · Sponsor: AstraZeneca

PhaseN/A

Planned participants600

Who can joinAll sexes, 18 Years to no upper limit

Healthy volunteersNo

About this study

A multicentre observational study on treatment approaches and HER2 positive status prevalence in different stages of bladder cancer and PD-L1-positive status in metastatic bladder cancer in Russian Federation

This description comes directly from the study's public registry record.

Talk to the study team

AstraZeneca Clinical Study Information Center · 1-877-240-9479 · information.center@astrazeneca.com

Always discuss trial participation with your own doctor first.

Locations (22)

Research Site	Arkhangelsk, Russia	Recruiting
Research Site	Barnaul, Russia	Recruiting
Research Site	Chelyabinsk, Russia	Recruiting
Research Site	Krasnodar, Russia	Recruiting
Research Site	Krasnoyarsk, Russia	Recruiting
Research Site	Makhachkala, Russia	Recruiting
Research Site	Moscow, Russia	Recruiting
Research Site	Moscow, Russia	Withdrawn
Research Site	Moscow, Russia	Not Yet Recruiting
Research Site	Nizhny Novgorod, Russia	Recruiting
Research Site	Novosibirsk, Russia	Withdrawn
Research Site	Obninsk, Russia	Not Yet Recruiting

+ 10 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07038928